{
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "document": "FlublokPI",
  "verification_stats": {
    "total_extracted": 2,
    "verified": 0,
    "rejected": 2,
    "verification_rate": 0.0
  },
  "verified_evidence": [],
  "rejected_evidence": [
    {
      "id": "comp_1",
      "quote": "Flublok contains recombinant Ha proteins of the three strains of influenza virus specified by health authorities for inclusion in the annual seasonal vaccine. These proteins function as antigens which induce a humoral immune response, measured by hem agglutination inhibition (HI) anti bod",
      "reason": "does not support claim",
      "original_explanation": "This quote explains that Flublok uses recombinant HA proteins from three different influenza strains to induce a humoral immune response, supporting the idea that recombinant technology can generate a broader immune response."
    },
    {
      "id": "comp_2",
      "quote": "Each of the three HAs is expressed in this cell line using abaculo virus vector (Autograph a cali for nica nuclear polyhedrosis virus), extracted from the cells with Triton X-100 and further purified by column chromatography. The purified HAs are then blended and filled into single dose syringes.",
      "reason": "does not support claim",
      "original_explanation": "This describes the recombinant process used to produce multiple hemagglutinin antigens, which is the technological basis for a broader immune response and potential cross-protection."
    }
  ],
  "model_used": "gpt-4.1"
}